| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alcoholic Cardiomyopathy–Attributed Mortality in the United States, 2010 to 2020
|
Zuin, Marco
|
|
|
13 |
7 |
p.
|
artikel
|
| 2 |
Association of the 2018 U.S. Heart Allocation Policy Change and the Survival Benefit of Heart Transplantation
|
Tolmie, Stratton B.
|
|
|
13 |
7 |
p.
|
artikel
|
| 3 |
Concomitant Surgical Procedures and Aspirin Avoidance With Left Ventricular Assist Device Therapy
|
Pagani, Francis D.
|
|
|
13 |
7 |
p.
|
artikel
|
| 4 |
Direct-to-Physician Marketing and Uptake of Optimal Medical Therapy for Heart Failure With Reduced Ejection Fraction
|
DeJong, Colette
|
|
|
13 |
7 |
p.
|
artikel
|
| 5 |
Editorial Board
|
|
|
|
13 |
7 |
p.
|
artikel
|
| 6 |
Exclusion of Liver Disease and Underutilization of Liver-Specific Endpoints in Heart Failure Trials
|
Khan, Muhammad Shahzeb
|
|
|
13 |
7 |
p.
|
artikel
|
| 7 |
Full issue PDF
|
|
|
|
13 |
7 |
p.
|
artikel
|
| 8 |
GDF-15 in Cardiovascular Disease
|
Di Vincenzo, Angelo
|
|
|
13 |
7 |
p.
|
artikel
|
| 9 |
GLP-1 Receptor Agonists in Heart Failure With Reduced Ejection Fraction
|
Neves, João Sérgio
|
|
|
13 |
7 |
p.
|
artikel
|
| 10 |
Interleukin-6 in Heart Failure With Reduced Ejection Fraction and the Effect of Dapagliflozin
|
Docherty, Kieran F.
|
|
|
13 |
7 |
p.
|
artikel
|
| 11 |
Promoting Representation in Heart Failure Clinical Trials
|
Gupta, Megha
|
|
|
13 |
7 |
p.
|
artikel
|
| 12 |
Publisher's Note
|
|
|
|
13 |
7 |
p.
|
artikel
|
| 13 |
Reply
|
Monzo, Luca
|
|
|
13 |
7 |
p.
|
artikel
|
| 14 |
Stroke in Heart Failure With Reduced Ejection Fraction
|
Gallone, Guglielmo
|
|
|
13 |
7 |
p.
|
artikel
|
| 15 |
The Antifibrotic Effects of Eplerenone in Hypertrophic Cardiomyopathy
|
Papapostolou, Stavroula
|
|
|
13 |
7 |
p.
|
artikel
|
| 16 |
Vasoplegia Syndrome After Cardiac Surgery
|
Castagna, Francesco
|
|
|
13 |
7 |
p.
|
artikel
|
| 17 |
When the Data Changes, So Should We
|
Silvestry, Scott C.
|
|
|
13 |
7 |
p.
|
artikel
|
Tijdschrift beschrijving